Organoids, three-dimensional cell cultures that mimic human tissue architecture, are being paired with AI and automation to accelerate drug discovery and preclinical testing, offering a more human-relevant alternative to outdated 2D cell cultures and animal models. For decades, pharmaceutical researchers have relied on flat, two-dimensional cell cultures and animal testing to predict how drugs will work in humans. The problem: they fail spectacularly. High failure rates in clinical trials persist despite technological advances, a phenomenon known as "Eroom's Law" (the inverse of Moore's Law), which illustrates how drug development has become increasingly inefficient over time . Now, a combination of organoid technology, artificial intelligence, and laboratory automation is reshaping how scientists discover and test new medicines.

What Are Organoids and Why Do They Matter for Drug Discovery?

Organoids are miniature, self-organizing biological systems derived from stem cells that replicate the structure and function of human organs far more accurately than traditional models. Unlike flat 2D cell cultures, which lack the complex cellular interactions found in real tissues, organoids recapitulate organ-specific functionality and enable researchers to model diseases, test drug efficacy and toxicity, and explore regenerative medicine approaches . Early studies have already demonstrated that organoids can predict patient responses to therapies more effectively than animal models. For example, researchers have used patient-derived tumor organoids to test cancer treatments, identifying therapies most likely to succeed in clinical trials .

The shift toward organoids reflects a broader recognition that traditional preclinical models have fundamental limitations. While 2D and simple spheroid cell cultures were originally derived from human tissues, they do not sufficiently mimic diverse cell interactions and tissue complexity. Animal studies, though historically the gold standard, do not account for human-specific genetic, molecular, and physiological differences . This gap between animal testing and human biology has driven pharmaceutical companies to seek alternatives.

How Are Regulatory Changes Accelerating Organoid Adoption?

Multiple forces are driving this shift toward human-relevant models. Regulatory agencies are actively encouraging alternatives to animal testing. In 2025, the FDA announced plans to phase out a requirement for animal testing in the development of monoclonal antibody therapies and other drugs, aiming to improve drug safety, accelerate the review process, and reduce research and development costs . In the United Kingdom, the Medicines and Healthcare products Regulatory Agency is now enabling an early review of non-animal data to give developers more confidence when making marketing applications based on evidence generated without animal testing .

Beyond regulatory support, the pharmaceutical industry's growing focus on complex drug modalities, such as antibody-based therapeutics and cell and gene therapies, has highlighted the inadequacy of traditional models. These therapies often rely on human-specific mechanisms that cannot be adequately studied in animals. Organoids, with their human-derived biology, provide a robust platform for testing these next-generation treatments .

Why Has Organoid Research Been So Difficult to Scale?

Despite their promise, organoids have presented a major challenge: culturing them has traditionally felt more like an art than a science. The process is labor-intensive, dependent on highly experienced personnel able to troubleshoot and adjust on the fly, and often takes weeks or even months of meticulous work to achieve the desired result . This artisanal approach is inherently variable, making scalability and reproducibility difficult to achieve. Brain organoids, for instance, require up to 90 days to mature, and the entire process has been difficult to standardize across different laboratories.

This is where automation and artificial intelligence make a critical impact. By replicating expert skill and delivering consistent results across labs and experiments, these technologies are transforming organoid research from a boutique practice into an industrial process .

How to Scale Organoid Research With Automation and AI

• Standardized Culture Conditions: Precision automation and robotics ensure that organoids are cultured under standardized conditions, preserving their quality and functionality across multiple experiments and locations.
• Real-Time Data Analysis: AI-powered platforms can analyze organoid development data in real-time, enabling researchers to make appropriate decisions efficiently about next steps in the culture process.
• Scalable Throughput: Automated cell culture platforms allow researchers to grow and maintain organoids with greater consistency and throughput, enabling the generation of large datasets needed for translational research.

Researchers at institutions like the University of California, Los Angeles and Emory University are pioneering the integration of automated cell culture platforms to scale organoid research. These systems streamline manual workflows and, together with AI-driven decision-making, reduce reliance on specialized personnel while ensuring that their expertise can be deployed across experiments and between different geographical sites to improve model reproducibility and data consistency . Brain organoids, which previously required up to 90 days to mature with highly variable results, can now be cultured more reliably at scale.

What Real-World Results Are Emerging From This Approach?

The adoption of organoid models, supported by automation, is already yielding promising results in drug discovery. Patient-derived tumor organoids have been used to test cancer treatments, identifying therapies most likely to succeed in clinical trials and bringing researchers closer to the promise of personalized medicine . The scalability, standardization, and transferability enabled by automation is also opening new avenues for collaboration. Dedicated organoid research centers and consortia, such as the NIH's organoid standardization initiative, are fostering knowledge-sharing and the development of best practices .

Meanwhile, the pharmaceutical industry is making substantial investments in AI-driven drug discovery platforms that complement organoid research. Takeda Pharmaceutical Company, for example, announced a multi-year collaboration with Iambic Therapeutics in February 2026 to apply AI-driven drug discovery toward small-molecule research programs . Under the agreement, Takeda gains access to Iambic's proprietary AI models, including the NeuralPLexer generative 3D structure predictor, and automated wet-lab capabilities initially focused on oncology, gastrointestinal, and inflammation targets . Iambic is eligible for up to $1.7 billion in development and sales milestones, reflecting the high-risk, high-reward nature of AI-driven discovery .

Iambic's track record provides validation for this approach. The company advanced an AI-designed HER2 inhibitor called IAM1363 from discovery to first-in-human clinical testing in under two years, well below the industry average . At ESMO 2025, Iambic disclosed that IAM1363 had shown clinical responses in heavily pretreated HER2-driven cancer patients, demonstrating that AI-designed drug candidates can deliver compelling clinical activity .

The convergence of organoid technology, automation, and artificial intelligence represents a fundamental shift in how pharmaceutical companies approach drug discovery. By moving away from outdated 2D cell cultures and animal models, and toward human-relevant organoid systems powered by AI and automation, the industry is addressing the productivity crisis that has plagued drug development for decades. As regulatory agencies continue to encourage alternatives to animal testing and as more pharmaceutical companies invest in these integrated platforms, organoid-based drug discovery is poised to accelerate the pace at which new therapies reach patients.